Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > BROWSE ARTICLES > Previous issues
26 Previous issues
Filter
Filter
Article type
Keywords
Authors
Funded articles
Volume 36(2); April 2021
Prev issue Next issue
In Memoriam
Miscellaneous
In Memoriam: Remembering Professor Hun-Ki Min (1928–2021)
Young Min Cho
Endocrinol Metab. 2021;36(2):207-208.   Published online April 20, 2021
DOI: https://doi.org/10.3803/EnM.2021.204
  • 3,152 View
  • 155 Download
PDFPubReader   ePub   
Close layer
Review Articles
Obesity and Metabolism
Food Preferences and Obesity
Sara Spinelli, Erminio Monteleone
Endocrinol Metab. 2021;36(2):209-219.   Published online April 19, 2021
DOI: https://doi.org/10.3803/EnM.2021.105
  • 6,829 View
  • 289 Download
  • 22 Web of Science
  • 22 Crossref
AbstractAbstract PDFPubReader   ePub   
Obesity is a multifactorial disease with several potential causes that remain incompletely understood. Recent changes in the environment, which has become increasingly obesogenic, have been found to interact with individual factors. Evidence of the role of taste responsiveness and food preference in obesity has been reported, pointing to a lower taste sensitivity and a higher preference and intake of fat and, to a lesser extent, sweet foods in obese people. Studies in the last decades have also suggested that individual differences in the neurophysiology of food reward may lead to overeating, contributing to obesity. However, further studies are needed to confirm these findings. In fact, only a limited number of studies has been conducted on large samples, and several studies were conducted only on women. Larger balanced studies in terms of sex/gender and age are required in order to control the confounding effect of these variables. As many factors are intertwined in obesity, a multidisciplinary approach is needed. This will allow a better understanding of taste alteration and food behaviours in obese people in order to design more effective strategies to promote healthier eating and to prevent obesity and the related chronic disease risks.

Citations

Citations to this article as recorded by  
  • Phytochemical composition, toxicological profiling and effect on pup birth weight of Corchorus olitorius leaf extract in rats: Implications for fetal macrosomia control
    Onyinye Mkpola Ukpai, Solomon Nnah Ijioma, Kingsley Kanu, Daniel Orieke, Peace Amarachi Chinedu-Ndukwe, Kingsley Chijioke Ugwuanyi, Eziuche Amadike Ugbogu
    Journal of Ethnopharmacology.2024; 319: 117170.     CrossRef
  • Exploring the factors influencing nutritional literacy based on the socioecological model among patients with age-related macular degeneration: a qualitative study from China
    Peilin Luo, Feng Zhang, Xin Li, Junli Wan, Wei Bian
    BMJ Open.2024; 14(5): e081468.     CrossRef
  • Sex Differences in Effects of Mood, Eating-Related Behaviors, and BMI on Food Appeal and Desire to Eat: A Cross-Sectional Survey Study
    Kristina T. Legget, Marc-Andre Cornier, Lauren Sarabia, Eve M. Delao, Susan K. Mikulich-Gilbertson, Crystal Natvig, Christina Erpelding, Tessa Mitchell, Allison Hild, Eugene Kronberg, Jason R. Tregellas
    Nutrients.2023; 15(3): 762.     CrossRef
  • Estimation of Free Sugars in the Filipino Food Composition Table and Evaluation of Population-Level Intake
    Fabio Mainardi, Vanessa Caroline Campos, Richard Gaston Côté, Nele Kristin Silber, Roko Plestina, Imelda Angeles-Agdeppa
    Nutrients.2023; 15(6): 1343.     CrossRef
  • Genetic Obesity in Pregnant Ay Mice Does Not Affect Susceptibility to Obesity and Food Choice in Offspring
    Elena Makarova, Anastasia Dubinina, Elena Denisova, Antonina Kazantseva
    International Journal of Molecular Sciences.2023; 24(6): 5610.     CrossRef
  • How Food Choices Impact College Going Students' Health in Urban Settings
    Nikita Yadav, Ms. Rhitika Sharma, Ms. Divyanshi Kapoor, Dr. Payal Mahajan
    International Journal of Scientific Research in Science and Technology.2023; : 774.     CrossRef
  • Mediators of the association between maternal body mass index and breastfeeding duration in 3 international cohorts
    Madeline Keyes, Chloe Andrews, Vishal Midya, Paula Carrasco, Mònica Guxens, Alba Jimeno-Romero, Mario Murcia, Cristina Rodriguez-Dehli, Dora Romaguera, Loreto Santa-Maria, Marina Vafeiadi, Lida Chatzi, Emily Oken, Martine Vrijheid, Damaskini Valvi, Sarbat
    The American Journal of Clinical Nutrition.2023; 118(1): 255.     CrossRef
  • Analysis of Determinants of Food Preferences in a Polish Population-Based Sample of Primary School Adolescents: Diet and Activity of Youth during COVID-19 (DAY-19) Study
    Aleksandra Kołota, Dominika Głąbska
    Nutrients.2023; 15(11): 2504.     CrossRef
  • Is obesity associated with taste alterations? a systematic review
    Beatriz Rodrigues Risuenho Peinado, Deborah Ribeiro Frazão, Leonardo Oliveira Bittencourt, Renata Duarte de Souza-Rodrigues, Maria Tereza Campos Vidigal, Douglas Teixeira da Silva, Luiz Renato Paranhos, Marcela Baraúna Magno, Nathalia Carolina Fernandes F
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Relationship between Dietary Intake and Adiposity in South African Female Adolescents: A Systematic Review
    Nokuthula Vilakazi, Sithabile Mathunjwa, Heather Legodi, Pedro Terrence Pisa
    Applied Sciences.2023; 13(19): 10813.     CrossRef
  • Fat mass and obesity-associated gene (FTO) rs9939609 (A/T) polymorphism and food preference in obese people with low-calorie intake and non-obese individuals with high-calorie intake
    Mehran Rahimlou, Bijan Ghobadian, Ali Ramezani, Ehsan Hejazi, Saeideh Mazloomzadeh, Jalal Hejazi
    BMC Nutrition.2023;[Epub]     CrossRef
  • The Role of the Olfactory System in Obesity and Metabolism in Humans: A Systematic Review and Meta-Analysis
    Lolita Matiashova, Anouk Lisa Hoogkamer, Katharina Timper
    Metabolites.2023; 14(1): 16.     CrossRef
  • Taste of Fat and Obesity: Different Hypotheses and Our Point of View
    Laurent Brondel, Didier Quilliot, Thomas Mouillot, Naim Akhtar Khan, Philip Bastable, Vincent Boggio, Corinne Leloup, Luc Pénicaud
    Nutrients.2022; 14(3): 555.     CrossRef
  • Long-Term Consumption of a Sugar-Sweetened Soft Drink in Combination with a Western-Type Diet Is Associated with Morphological and Molecular Changes of Taste Markers Independent of Body Weight Development in Mice
    Barbara Lieder, Jozef Čonka, Agnes T. Reiner, Victoria Zabel, Dominik Ameur, Mark M. Somoza, Katarína Šebeková, Peter Celec, Veronika Somoza
    Nutrients.2022; 14(3): 594.     CrossRef
  • Phenotyping of Drosophila Melanogaster—A Nutritional Perspective
    Virginia Eickelberg, Kai Lüersen, Stefanie Staats, Gerald Rimbach
    Biomolecules.2022; 12(2): 221.     CrossRef
  • Consumer Expectation of Flavored Water Function, Sensory Quality, and Sugar Reduction, and the Impact of Demographic Variables and Woman Consumer Segment
    Uijeong An, Xiaofen Du, Wanyi Wang
    Foods.2022; 11(10): 1434.     CrossRef
  • Sex as an independent variable in the measurement of satiation: a retrospective cohort study
    Maria D. Hurtado, Lizeth Cifuentes, Alejandro Campos, Alan De La Rosa, Ekta Kapoor, Stephanie S. Faubion, Donald D. Hensrud, Michael Camilleri, Andres Acosta
    International Journal of Obesity.2022; 46(12): 2156.     CrossRef
  • Associations between Overweight and Obesity and Common Mental Disorders and Eating Behaviors of Adult Women
    Ana Clara Justino Valencio, Andressa Bueno Antunes, Lilian Fonseca, Julia Araujo, Maria Clara Goyer Silva, Marcia Costa, Juliana Gomes e Silva Czermainski, Carolina Böettge Rosa, Chaline Caren Coghetto, Randhall Bruce Carteri
    Obesities.2022; 2(4): 350.     CrossRef
  • Appetitive Motivation and Associated Neurobiology Change Differentially across the Life Course of Mouse Offspring Exposed to Peri- and Postnatal High Fat Feeding
    Laura Contu, Christopher J. Heath, Cheryl A. Hawkes
    Nutrients.2022; 14(23): 5161.     CrossRef
  • Toward a Better Understanding of Diet–Taste Relations
    Beverly J Tepper
    The Journal of Nutrition.2021; 151(9): 2503.     CrossRef
  • The Same Metabolic Response to FGF21 Administration in Male and Female Obese Mice Is Accompanied by Sex-Specific Changes in Adipose Tissue Gene Expression
    Elena Makarova, Antonina Kazantseva, Anastasia Dubinina, Tatiana Jakovleva, Natalia Balybina, Konstantin Baranov, Nadezhda Bazhan
    International Journal of Molecular Sciences.2021; 22(19): 10561.     CrossRef
  • Influence of leptin administration to pregnant female mice on obesity development, taste preferences, and gene expression in the liver and muscles of their male and female offspring
    E. I. Denisova, M. M. Savinkova, E. N. Makarova
    Vavilov Journal of Genetics and Breeding.2021; 25(6): 669.     CrossRef
Close layer
Obesity and Metabolism
Digital Therapeutics for Obesity and Eating-Related Problems
Meelim Kim, Hyung Jin Choi
Endocrinol Metab. 2021;36(2):220-228.   Published online March 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.107
  • 9,955 View
  • 421 Download
  • 16 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   ePub   
In recent years, digital technologies have rapidly advanced and are being applied to remedy medical problems. These technologies allow us to monitor and manage our physical and mental health in our daily lives. Since lifestyle modification is the cornerstone of the management of obesity and eating behavior problems, digital therapeutics (DTx) represent a powerful and easily accessible treatment modality. This review discusses the critical issues to consider for enhancing the efficacy of DTx in future development initiatives. To competently adapt and expand public access to DTx, it is important for various stakeholders, including health professionals, patients, and guardians, to collaborate with other industry partners and policy-makers in the ecosystem.

Citations

Citations to this article as recorded by  
  • KIOS: A smartphone app for self‐monitoring for patients with bipolar disorder
    Mehak Pahwa, Susan L. McElroy, Richard Priesmeyer, Gregg Siegel, Phyllis Siegel, Sharon Nuss, Charles L. Bowden, Rif S. El‐Mallakh
    Bipolar Disorders.2024; 26(1): 84.     CrossRef
  • What digital health technology types are used in mental health prevention and intervention? Review of systematic reviews for systematization of technologies
    Naomichi Tani, Hiroaki Fujihara, Kenji Ishii, Yoshiyuki Kamakura, Mafu Tsunemi, Chikae Yamaguchi, Hisashi Eguchi, Kotaro Imamura, Satoru Kanamori, Noriko Kojimahara, Takeshi Ebara
    Journal of Occupational Health.2024;[Epub]     CrossRef
  • Randomized controlled trial of digital therapeutics for temporomandibular disorder: A pilot study
    Sang-Yoon Park, Soo-Hwan Byun, Byoung-Eun Yang, Daehyun Kim, Bongju Kim, Jong-Ho Lee, Young-Kyun Kim
    Journal of Dentistry.2024; 147: 105030.     CrossRef
  • Comparing the Efficacy of Digital and In-Person Weight Loss Interventions for Patients with Obesity and Glycemic Disorders: Evidence from a Randomized Non-Inferiority Trial
    Katarína Moravcová, Markéta Sovová, Jaromír Ožana, Martina Karbanová, Jan Klásek, Agnieszka Barbara Kolasińska, Eliška Sovová
    Nutrients.2024; 16(10): 1510.     CrossRef
  • Feasibility and Acceptability Evaluation of a Digital Therapeutic Program for Improving Cancer Prevention: A Quasi-experimental Pre-post Interventional Pilot Study
    Xianwei Zhang, Sheng Zhang, Haiyan Zhang, Ziyou Xiong, Yi Li, Lufeng Li, Xitian Pi, Hongying Liu
    Journal of Cancer Education.2024;[Epub]     CrossRef
  • Digital therapeutics from bench to bedside
    Changwon Wang, Chungkeun Lee, Hangsik Shin
    npj Digital Medicine.2023;[Epub]     CrossRef
  • Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease
    Run Zhou, Yunpeng Gu, Binbin Zhang, Tingting Kong, Wei Zhang, Jie Li, Junping Shi
    Clinical and Translational Gastroenterology.2023; 14(4): e00575.     CrossRef
  • Digital Therapeutics as a New Therapeutic Modality: A Review from the Perspective of Clinical Pharmacology
    Benjamin Ribba, Richard Peck, Lucy Hutchinson, Imein Bousnina, Dario Motti
    Clinical Pharmacology & Therapeutics.2023; 114(3): 578.     CrossRef
  • eHealth in obesity care
    Bukhosi Raymond Sithole, Yannis Pappas, Gurch Randhawa
    Clinical Medicine.2023; 23(4): 347.     CrossRef
  • Strategies for Long-Term Weight Loss and Maintenance
    Yoo-Bin Seo
    Korean Journal of Family Practice.2023; 13(3): 128.     CrossRef
  • Implications of immersive technologies in healthcare sector and its built environment
    Eunsil Yang
    Frontiers in Medical Technology.2023;[Epub]     CrossRef
  • Cost-effectiveness analysis of digital therapeutics for home-based cardiac rehabilitation for patients with atrial fibrillation after catheter ablation
    Tianyi Liu, Zhijie Tang, Cheng Cai, Nan Wu, Jian Jia, Gang Yang, Wenhong Zhang
    DIGITAL HEALTH.2023;[Epub]     CrossRef
  • Cost-effectiveness analysis of digital therapeutics for home-based cardiac rehabilitation for patients with chronic heart failure: model development and data analysis
    Tianyi Liu, Yiyang Zhan, Silei Chen, Wenhong Zhang, Jian Jia
    Cost Effectiveness and Resource Allocation.2023;[Epub]     CrossRef
  • Comprehensive traditional East Asian medicine treatment strategy for obesity considering the therapeutic effects and adverse events
    Hongmin Chu, Byungsoo Kang, Bo-Young Youn, Kwan-il Kim, Jinbong Park, Jungtae Leem
    Medicine.2022; 101(6): e28673.     CrossRef
  • Clinical Evaluation of Digital Therapeutics: Present and Future
    Ki Young Huh, Jaeseong Oh, SeungHwan Lee, Kyung-Sang Yu
    Healthcare Informatics Research.2022; 28(3): 188.     CrossRef
  • Health-Related Indicators Measured Using Earable Devices: Systematic Review
    Jin-Young Choi, Seonghee Jeon, Hana Kim, Jaeyoung Ha, Gyeong-suk Jeon, Jeong Lee, Sung-il Cho
    JMIR mHealth and uHealth.2022; 10(11): e36696.     CrossRef
  • Clinical Efficacy of a Digital Intervention for Patients with Atopic Dermatitis: a Prospective Single-Center Study
    Sigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L. Ámundadóttir, Judit Mészáros, Jenna H. Eysteinsdóttir, Ragna H. Thorleifsdóttir, Sigrídur K. Hrafnkelsdóttir, Heida B. Bragadóttir, Saemundur Oddsson, Jonathan I. Silverberg
    Dermatology and Therapy.2022; 12(11): 2601.     CrossRef
Close layer
Obesity and Metabolism
Dopaminergic Control of the Feeding Circuit
Ja-Hyun Baik
Endocrinol Metab. 2021;36(2):229-239.   Published online April 6, 2021
DOI: https://doi.org/10.3803/EnM.2021.979
  • 9,649 View
  • 486 Download
  • 15 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   ePub   
There is increasing evidence demonstrating that reward-related motivational food intake is closely connected with the brain’s homeostatic system of energy balance and that this interaction might be important in the integrative control of feeding behavior. Dopamine regulates motivational behavior, including feeding behaviors, and the dopamine reward system is recognized as the most prominent system that controls appetite and motivational and emotional drives for food. It appears that the dopamine system exerts a critical role in the control of feeding behavior not only by the reward-related circuit, but also by contributing to the homeostatic circuit of food intake, suggesting that dopamine plays an integrative role across the converging circuitry of control of food intake by linking energy state-associated signals to reward-related behaviors. This review will cover and discuss up-to-date findings on the dopaminergic control of food intake by both the reward-related circuit and the homeostatic hypothalamic system.

Citations

Citations to this article as recorded by  
  • Cross-cultural adaptation and psychometric investigation of the palatable eating motives scale (PEMS) for a sample of Brazilian adults
    Priscila Carvalho Santos, Wanderson Roberto da Silva, João Marôco, Juliana Alvares Duarte Bonini Campos
    Current Psychology.2024; 43(7): 6360.     CrossRef
  • The Calmodulin-interacting peptide Pcp4a regulates feeding state-dependent behavioral choice in zebrafish
    Margherita Zaupa, Nagarjuna Nagaraj, Anna Sylenko, Herwig Baier, Suphansa Sawamiphak, Alessandro Filosa
    Neuron.2024; 112(7): 1150.     CrossRef
  • Maternal nanoplastic ingestion induces an increase in offspring body weight through altered lipid species and microbiota
    Bohyeon Jeong, Ji-Sun Kim, A Ra Kwon, Jangjae Lee, Subin Park, Jahong Koo, Wang Sik Lee, Jeong Yeob Baek, Won-Ho Shin, Jung-Sook Lee, Jinyoung Jeong, Won Kon Kim, Cho-Rok Jung, Nam-Soon Kim, Sung-Hee Cho, Da Yong Lee
    Environment International.2024; 185: 108522.     CrossRef
  • Satiety: a gut–brain–relationship
    Ghinwa M. Barakat, Wiam Ramadan, Ghaith Assi, Noura B. El Khoury
    The Journal of Physiological Sciences.2024;[Epub]     CrossRef
  • Effect of Probiotic Lacticaseibacillus rhamnosus LB1.5 on Anxiety-like Behavior, Neuroprotection and Neuroinflammation Markers of Male Mice Fed a High-Fat Diet
    Natália Perin Schmidt, Patrícia Molz, Brenda Santos Fraga, Nicole Hiller Bondarczuk, Priscila Dutra Silveira, Milena Henrique Ferri, Thais Busatto Crestani, Gabriela Merker Breyer, Giuliano Rizzoto Guimarães, Amanda de Souza da Motta, Renata Padilha Guede
    Nutrients.2024; 16(6): 879.     CrossRef
  • Repeated binge‐like eating episodes in female rats alter adenosine A2A and dopamine D2 receptor genes regulation in the brain reward system
    Francesca Mercante, Emanuela Micioni Di Bonaventura, Mariangela Pucci, Luca Botticelli, Carlo Cifani, Claudio D'Addario, Maria Vittoria Micioni Di Bonaventura
    International Journal of Eating Disorders.2024;[Epub]     CrossRef
  • Traditional Japanese medicine Kamikihito ameliorates sucrose preference, chronic inflammation and obesity induced by a high fat diet in middle-aged mice
    Yuko Maejima, Shoko Yokota, Megumi Yamachi, Shingen Misaka, Tomoyuki Ono, Hiroaki Oizumi, Keita Mizuno, Shizu Hidema, Katsuhiko Nishimori, Masato Aoyama, Heidi de Wet, Kenju Shimomura
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Retracted : Pan‐neuronal knockdown of Ras GTPase‐activating protein 1 alters Drosophila activity and sleep behavior
    Francisco Alejandro Lagunas‐Rangel
    Archives of Insect Biochemistry and Physiology.2023;[Epub]     CrossRef
  • Maternal Over- and Malnutrition and Increased Risk for Addictive and Eating Disorders in the Offspring
    Mathilde C. C. Guillaumin, Daria Peleg-Raibstein
    Nutrients.2023; 15(5): 1095.     CrossRef
  • Carving the senescent phenotype by the chemical reactivity of catecholamines: An integrative review
    Aleksei G. Golubev
    Ageing Research Reviews.2022; 75: 101570.     CrossRef
  • Obesity I: Overview and molecular and biochemical mechanisms
    Robert H. Lustig, David Collier, Christopher Kassotis, Troy A. Roepke, Min Ji Kim, Etienne Blanc, Robert Barouki, Amita Bansal, Matthew C. Cave, Saurabh Chatterjee, Mahua Choudhury, Michael Gilbertson, Dominique Lagadic-Gossmann, Sarah Howard, Lars Lind,
    Biochemical Pharmacology.2022; 199: 115012.     CrossRef
  • Food preferences and thyroid hormones in children and adolescents with obesity
    Daniela Staníková, Lea Krajčovičová, Linda Demková, Petronela Forišek-Paulová, Lucia Slobodová, Eva Vitariušová, Lubica Tichá, Barbara Ukropcová, Juraj Staník, Jozef Ukropec
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Dopamine systems and biological rhythms: Let’s get a move on
    Qijun Tang, Dina R. Assali, Ali D. Güler, Andrew D. Steele
    Frontiers in Integrative Neuroscience.2022;[Epub]     CrossRef
  • Suprachiasmatic to paraventricular nuclei interaction generates normal food searching rhythms in mice
    Iwona Olejniczak, Benjamin Campbell, Yuan-Chen Tsai, Shiva K. Tyagarajan, Urs Albrecht, Jürgen A. Ripperger
    Frontiers in Physiology.2022;[Epub]     CrossRef
  • THE ROLE OF CIRCADIAN REGULATION OF GHRELIN LEVELS IN PARKINSON’S DISEASE (LITERATURE REVIEW)
    Kateryna A. Tarianyk, Nataliya V. Lytvynenko, Anastasiia D. Shkodina, Igor P. Kaidashev
    Wiadomości Lekarskie.2021; 74(7): 1750.     CrossRef
Close layer
Diabetes
Continuous Glucose Monitoring in the Hospital
M. Citlalli Perez-Guzman, Trisha Shang, Jennifer Y. Zhang, Donna Jornsay, David C. Klonoff
Endocrinol Metab. 2021;36(2):240-255.   Published online March 31, 2021
DOI: https://doi.org/10.3803/EnM.2021.201
  • 17,958 View
  • 689 Download
  • 28 Web of Science
  • 24 Crossref
AbstractAbstract PDFPubReader   ePub   
Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes; the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes.

Citations

Citations to this article as recorded by  
  • Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System
    Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park
    Diabetes Technology & Therapeutics.2024; 26(4): 222.     CrossRef
  • Glucose management in critically ill adults: A qualitative study from the experiences of health care providers
    Miao Huang, Li Yang, Chuanlai Zhang, Xiuni Gan
    Heliyon.2024; 10(3): e24545.     CrossRef
  • Summary of clinical investigation plan for The DIATEC trial: in-hospital diabetes management by a diabetes team and continuous glucose monitoring or point of care glucose testing – a randomised controlled trial
    Mikkel Thor Olsen, Carina Kirstine Klarskov, Ulrik Pedersen-Bjergaard, Katrine Bagge Hansen, Peter Lommer Kristensen
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Nurses’ practice of metabolic monitoring for patients on antipsychotics in Lesotho
    Relebohile P. Matete, Libuseng M. Rathobei
    South African Journal of Psychiatry.2024;[Epub]     CrossRef
  • The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record
    Juan Espinoza, Nicole Y. Xu, Kevin T. Nguyen, David C. Klonoff
    Journal of Diabetes Science and Technology.2023; 17(2): 495.     CrossRef
  • Staff knowledge, attitudes and practices regarding glycaemic management in adult intensive care units: A national survey
    Miao Huang, Ruiqi Yang, Chuanlai Zhang, Xiuni Gan
    Nursing in Critical Care.2023; 28(6): 931.     CrossRef
  • Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center
    Adrian G. Dumitrascu, Michelle F. Perry, Rebecca J. Boone, Maria P. Guzman, Razvan M. Chirila, Allyson W. McNally, Dorin T. Colibaseanu, Shon E. Meek, Colleen T. Ball, Launia J. White, Ana-Maria Chindris
    Endocrine Practice.2023; 29(3): 155.     CrossRef
  • Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations
    Jared G Friedman, Zulma Cardona Matos, Emily D Szmuilowicz, Grazia Aleppo
    Pharmacogenomics and Personalized Medicine.2023; Volume 16: 263.     CrossRef
  • Type 1 Diabetes Overview and Perioperative Management
    Grace B. Nelson, Kathryn M. Sumpter
    Orthopedic Clinics of North America.2023; 54(3): 287.     CrossRef
  • Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
    Samantha R. Spierling Bagsic, Addie L. Fortmann, Rebekah Belasco, Alessandra Bastian, Suzanne Lohnes, Anna Ritko, Haley Sandoval, Mariya Chichmarenko, Emily C. Soriano, Laura Talavera, Athena Philis-Tsimikas
    Journal of Diabetes Science and Technology.2023; 17(3): 656.     CrossRef
  • Implementation of Continuous Glucose Monitoring in Critical Care: A Scoping Review
    Eileen R. Faulds, Kathleen M. Dungan, Molly McNett
    Current Diabetes Reports.2023; 23(6): 69.     CrossRef
  • Clinical Use of Continuous Glucose Monitoring in Critically Ill Pediatric Patients with Diabetic Ketoacidosis
    Esther Park, Minsun Kim
    Diabetes Technology & Therapeutics.2023; 25(8): 529.     CrossRef
  • Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality
    Ji Yoon Kim, Jee Hee Yoo, Jae Hyeon Kim
    Diabetes Technology & Therapeutics.2023; 25(12): 883.     CrossRef
  • A randomized trial of continuous glucose monitoring to improve post‐transplant glycemic control
    Nicholas Jandovitz, Sam J. George, Mersema Abate, Adam M. Kressel, Alexandra C. Bolognese, Lawrence Lau, Vinay Nair, Elliot Grodstein
    Clinical Transplantation.2023;[Epub]     CrossRef
  • More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data
    Richard M. Bergenstal, Gregg D. Simonson, Lutz Heinemann
    Journal of Diabetes Science and Technology.2022; 16(1): 3.     CrossRef
  • Continuous glucose monitoring in the hospital: an update in the era of COVID-19
    Chikara Gothong, Lakshmi G. Singh, Medha Satyarengga, Elias K. Spanakis
    Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(1): 1.     CrossRef
  • Breakthrough technology for in-hospital glucose monitoring
    David Kerr, David Klonoff
    The Lancet Diabetes & Endocrinology.2022; 10(5): 304.     CrossRef
  • The Role of the Diabetes Care and Education Specialist in the Hospital Setting

    The Science of Diabetes Self-Management and Care.2022; 48(3): 184.     CrossRef
  • Real-Time Monitoring of Blood Parameters in the Intensive Care Unit: State-of-the-Art and Perspectives
    Rebecca Bockholt, Shaleen Paschke, Lars Heubner, Bergoi Ibarlucea, Alexander Laupp, Željko Janićijević, Stephanie Klinghammer, Sascha Balakin, Manfred F. Maitz, Carsten Werner, Gianaurelio Cuniberti, Larysa Baraban, Peter Markus Spieth
    Journal of Clinical Medicine.2022; 11(9): 2408.     CrossRef
  • Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
    Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Stress-Induced Hyperglycemia: Consequences and Management
    Deepanjali Vedantam, Devyani S Poman, Lakshya Motwani, Nailah Asif, Apurva Patel, Krishna Kishore Anne
    Cureus.2022;[Epub]     CrossRef
  • Hospital Diabetes Meeting 2022
    Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Math
    Journal of Diabetes Science and Technology.2022; 16(5): 1309.     CrossRef
  • Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study
    Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho
    Diabetes Care.2022; 45(10): 2224.     CrossRef
  • The Devil Is in the Details: Use, Limitations, and Implementation of Continuous Glucose Monitoring in the Inpatient Setting
    Rebecca Rick Longo, Renu Joshi
    Diabetes Spectrum.2022; 35(4): 405.     CrossRef
Close layer
Diabetes
Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney
Endocrinol Metab. 2021;36(2):256-269.   Published online April 19, 2021
DOI: https://doi.org/10.3803/EnM.2021.987
  • 6,300 View
  • 304 Download
  • 10 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   ePub   
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.

Citations

Citations to this article as recorded by  
  • Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
    Soumitra Ray, J Ezhilan, Rajiv Karnik, Ashish Prasad, Rajashree Dhar
    Journal of Diabetology.2024; 15(2): 131.     CrossRef
  • The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
    Mustafa Arici, Bulent Altun, Mustafa Araz, Aysegul Atmaca, Tevfik Demir, Tevfik Ecder, Galip Guz, Dilek Gogas Yavuz, Alaattin Yildiz, Temel Yilmaz
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD
    Ayodele Odutayo, Adeera Levin
    Clinical Journal of the American Society of Nephrology.2023; 18(5): 557.     CrossRef
  • Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
    Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
    Endocrinology and Metabolism.2023; 38(1): 43.     CrossRef
  • Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
    Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
    Endocrinology and Metabolism.2023; 38(4): 359.     CrossRef
  • SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
    A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee
    Biomedicine & Pharmacotherapy.2023; 168: 115755.     CrossRef
  • Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
    Emma S. Speedtsberg, Martin Tepel
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Management of CKD
    Nimrit Goraya, Jennifer D. Moran
    Nephrology Self-Assessment Program.2022; 21(2): 146.     CrossRef
  • Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
    Peter Kolkhof, Amer Joseph, Ulrich Kintscher
    Pharmacological Research.2021; 172: 105859.     CrossRef
  • Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression
    Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
    Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz
    touchREVIEWS in Endocrinology.2021; 17(2): 84.     CrossRef
  • Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
    Jorge I. Fonseca-Correa, Ricardo Correa-Rotter
    Frontiers in Medicine.2021;[Epub]     CrossRef
Close layer
Bone Metabolism
Operationalizing Treat-to-Target for Osteoporosis
E. Michael Lewiecki
Endocrinol Metab. 2021;36(2):270-278.   Published online March 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.970
  • 5,993 View
  • 311 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Treat-to-target (TTT) for osteoporosis is a concept for individualizing patient treatment decisions that focuses on achieving an acceptable level of fracture risk rather than response to treatment alone. While a response to treatment is essential in order to achieve an acceptable level of risk, it is not necessarily sufficient. Some patients have a good response to treatment yet remain at high level of fracture risk. Since there is no way to directly measure bone strength in patients treated for osteoporosis, a surrogate measurement must be used. Bone mineral density (BMD) is commonly used to select patients for treatment and has emerged as the most useful surrogate for assessing reduction of fracture risk after treatment is started. Recent large meta-regression studies have shown a robust correlation between larger increases in BMD with treatment and greater reductions in fracture risk. Application of TTT for osteoporosis involves assessing fracture risk before starting treatment and initiating treatment with an agent that is most likely to reduce fracture risk to an acceptable level, represented by a target BMD T-score, over a reasonable period of time. This review offers suggestions for implementing TTT for osteoporosis in clinical practice and managing patients who fail or succeed in reaching the target. More study is needed to fully validate the use of TTT for osteoporosis for initiating and modifying treatments to reduce fracture risk.

Citations

Citations to this article as recorded by  
  • Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss
    Anna Thorsø Larsen, Morten A. Karsdal, Kim Henriksen
    European Journal of Pharmacology.2023; 954: 175837.     CrossRef
  • Osteoporosis: Spotlight on current approaches to pharmacological treatment
    Dilşad Sindel
    Turkish Journal of Physical Medicine and Rehabilitation.2023; 69(2): 140.     CrossRef
  • Postmenopausal Osteoporosis
    Caren G. Solomon, Marcella Donovan Walker, Elizabeth Shane
    New England Journal of Medicine.2023; 389(21): 1979.     CrossRef
  • Prevalence and Risk Factors of T-Score Spine-Hip Discordance in Patients with Osteoporotic Vertebral Compression Fracture
    Byung-Ho Yoon, Ho Won Kang, Su Min Kim, Young Do Koh
    Journal of Bone Metabolism.2022; 29(1): 43.     CrossRef
  • Pharmacological treatment of osteoporosis: 2022 update
    Yunkyung Jeon, In-Joo Kim
    Journal of the Korean Medical Association.2022; 65(4): 241.     CrossRef
Close layer
Obesity and Metabolism
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam
Endocrinol Metab. 2021;36(2):279-295.   Published online April 19, 2021
DOI: https://doi.org/10.3803/EnM.2021.964
  • 6,982 View
  • 304 Download
  • 16 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   ePub   
Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require additional lipid-modifying therapies. Drugs that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) offer a novel approach to reduce LDL-C. The monoclonal antibodies, alirocumab and evolocumab, given by subcutaneous injection every 2 or 4 weeks produce reductions in LDL-C of 50% to 60% in patients with HeFH, allowing many of them to achieve their LDL-C goals. Patients with HoFH show a reduced and more variable LDL-C response, which appears to depend on residual LDL receptor activity, and those with receptor-negative mutations may show no response. Inclisiran is a long-acting small interfering RNA therapeutic agent that inhibits the synthesis of PCSK9. Subcutaneous doses of 300 mg can reduce LDL-C by more than 50% for at least 6 months and the responses in HeFH and HoFH patients are similar to those achieved with monoclonal antibodies. These PCSK9 inhibitors are generally well tolerated and they provide a new opportunity for effective treatment for the majority of patients with FH.

Citations

Citations to this article as recorded by  
  • Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium
    Marc Snel, Olivier S. Descamps
    Acta Cardiologica.2024; 79(3): 311.     CrossRef
  • Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors
    Ryosuke Tani, Keiji Matsunaga, Yuta Toda, Tomoko Inoue, Hai Ying Fu, Tetsuo Minamino
    Clinical Case Reports.2024;[Epub]     CrossRef
  • Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
    Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari-Shafti
    Cardiology and Therapy.2024; 13(1): 39.     CrossRef
  • Technologies of gene editing and related clinical trials for the treatment of genetic and acquired diseases: a systematic review
    Wessam Sharaf-Eldin
    Egyptian Journal of Medical Human Genetics.2024;[Epub]     CrossRef
  • Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
    Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio
    Annals of Medicine & Surgery.2024; 86(5): 2818.     CrossRef
  • Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary Angiography
    Narae Kim, Jin-Man Cho, In-Ho Yang
    Biomedicines.2024; 12(5): 1113.     CrossRef
  • Qualitative and Quantitative Effects of PCSK9 Inhibitors in familial Hypercholesterolemia: a Synthetic Review
    Aamina Shakir, Kyle Barron, Kalgi Modi
    Current Problems in Cardiology.2023; 48(4): 101550.     CrossRef
  • Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression
    Peng Ye, Xiao-Min Jiang, Wei-Chun Qian, Juan Zhang
    Cardiovascular Drugs and Therapy.2023;[Epub]     CrossRef
  • Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic
    Helen Huang, Keith S. K. Leung, Tulika Garg, Adele Mazzoleni, Goshen D. Miteu, Farida Zakariya, Wireko A. Awuah, Elaine T. S. Yin, Faaraea Haroon, Zarish Hussain, Narjiss Aji, Vikash Jaiswal, Gary Tse
    Clinical Cardiology.2023; 46(8): 831.     CrossRef
  • Familial Hypercholesterolemia in Children. The Current State of the Problem
    Dinara I. Sadykova, Karina R. Salakhova, Liliya F. Galimova, Eugeniya S. Slastnikova, Chulpan D. Khaliullina
    Current Pediatrics.2023; 22(3): 231.     CrossRef
  • PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
    Juan Vicente-Valor, Xandra García-González, Sara Ibáñez-García, María Esther Durán-García, Ana de Lorenzo-Pinto, Carmen Rodríguez-González, Irene Méndez-Fernández, Juan Carlos Percovich-Hualpa, Ana Herranz-Alonso, María Sanjurjo-Sáez
    Biomedicine & Pharmacotherapy.2022; 146: 112519.     CrossRef
  • Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
    Shakir Ahamad, Shintu Mathew, Waqas A. Khan, Kishor Mohanan
    Drug Discovery Today.2022; 27(5): 1332.     CrossRef
  • The biological relevance of PCSK9: when less is better…
    Majambu Mbikay, Michel Chrétien
    Biochemistry and Cell Biology.2022; 100(3): 189.     CrossRef
  • Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Metabolism.2022; 137: 155327.     CrossRef
  • Homozygous Familial Hypercholesterolemia
    Lisa Young, Emily E. Brown, Seth S. Martin
    JACC: Case Reports.2022; 4(23): 101666.     CrossRef
  • Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis
    Kristina Zubielienė, Gintarė Valterytė, Neda Jonaitienė, Diana Žaliaduonytė, Vytautas Zabiela
    Medicina.2022; 58(11): 1665.     CrossRef
  • Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
    Eric Bruckert, Sonia Caprio, Albert Wiegman, Min-Ji Charng, Cézar A. Zárate-Morales, Marie T. Baccara-Dinet, Garen Manvelian, Anne Ourliac, Michel Scemama, Stephen R. Daniels
    Arteriosclerosis, Thrombosis, and Vascular Biology.2022; 42(12): 1447.     CrossRef
Close layer
Obesity and Metabolism
An Update on Contraception in Polycystic Ovary Syndrome
Seda Hanife Oguz, Bulent Okan Yildiz
Endocrinol Metab. 2021;36(2):296-311.   Published online April 15, 2021
DOI: https://doi.org/10.3803/EnM.2021.958
  • 13,124 View
  • 805 Download
  • 15 Web of Science
  • 19 Crossref
AbstractAbstract PDFPubReader   ePub   
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in reproductive-aged women, characterized by hyperandrogenism, oligo/anovulation, and polycystic ovarian morphology. Combined oral contraceptives (COCs), along with lifestyle modifications, represent the first-line medical treatment for the long-term management of PCOS. Containing low doses of estrogen and different types of progestin, COCs restore menstrual cyclicity, improve hyperandrogenism, and provide additional benefits such as reducing the risk of endometrial cancer. However, potential cardiometabolic risk associated with these agents has been a concern. COCs increase the risk of venous thromboembolism (VTE), related both to the dose of estrogen and the type of progestin involved. Arterial thrombotic events related to COC use occur much less frequently, and usually not a concern for young patients. All patients diagnosed with PCOS should be carefully evaluated for cardiometabolic risk factors at baseline, before initiating a COC. Age, smoking, obesity, glucose intolerance or diabetes, hypertension, dyslipidemia, thrombophilia, and family history of VTE should be recorded. Patients should be re-assessed at consecutive visits, more closely if any baseline cardiometabolic risk factor is present. Individual risk assessment is the key in order to avoid unfavorable outcomes related to COC use in women with PCOS.

Citations

Citations to this article as recorded by  
  • Clinical management of androgen excess and defect in women
    Elena Rosato, Francesca Sciarra, Marianna Minnetti, Anisa Degjoni, Mary Anna Venneri
    Expert Review of Endocrinology & Metabolism.2024; 19(1): 21.     CrossRef
  • Il rischio tromboembolico nella sindrome dell’ovaio policistico
    Davide Ceccato, Francesca Dassie, Pietro Maffei, Roberto Mioni
    L'Endocrinologo.2024; 25(2): 151.     CrossRef
  • The ameliorating effects of apigenin and chrysin alone and in combination on polycystic ovary syndrome induced by dehydroepiandrosterone in rats
    Buket Berk, Nevin İlhan, Solmaz Susam, Fatma Tedik, Nalan Kaya Tektemur
    Marmara Medical Journal.2024; 37(2): 198.     CrossRef
  • Changes in the serum metabolomics of polycystic ovary syndrome before and after compound oral contraceptive treatment
    Ting Zhao, Xiao Xiao, Lingchuan Li, Jing Zhu, Wenli He, Qiong Zhang, Jiaqi Wu, Xiaomei Wu, Tao Yuan
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Association Between Intrauterine System Hormone Dosage and Depression Risk
    Søren Vinther Larsen, Anders Pretzmann Mikkelsen, Brice Ozenne, Trine Munk-Olsen, Øjvind Lidegaard, Vibe Gedso Frokjaer
    American Journal of Psychiatry.2024;[Epub]     CrossRef
  • Current and emerging drug treatment strategies for polycystic ovary syndrome
    Nafiye Helvaci, Bulent Okan Yildiz
    Expert Opinion on Pharmacotherapy.2023; 24(1): 105.     CrossRef
  • Weighted Gene Co-Expression Network Analysis (WGCNA) Discovered Novel Long Non-Coding RNAs for Polycystic Ovary Syndrome
    Roozbeh Heidarzadehpilehrood, Maryam Pirhoushiaran, Malina Binti Osman, Habibah Abdul Hamid, King-Hwa Ling
    Biomedicines.2023; 11(2): 518.     CrossRef
  • The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking
    Mali Wu, Hua Liu, Jie Zhang, Fangfang Dai, Yiping Gong, Yanxiang Cheng
    Journal of Pharmacy & Pharmaceutical Sciences.2023;[Epub]     CrossRef
  • Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome
    Carmen Pingarrón Santofímia, Silvia Poyo Torcal, Helena López Verdú, Alexandra Henríquez Linares, Virginia Calvente Aguilar, Pablo Terol Sánchez, María Sol Martínez García, Pilar Lafuente González
    Gynecological Endocrinology.2023;[Epub]     CrossRef
  • Contemporary Management of the Patient with Polycystic Ovary Syndrome
    Nicolás Omar Francone, Tia Ramirez, Christina E. Boots
    Obstetrics and Gynecology Clinics of North America.2023; 50(4): 695.     CrossRef
  • Challenges in diagnosis and health care in polycystic ovary syndrome in Canada: a patient view to improve health care
    Beate C. Sydora, Michaelann S. Wilke, Maggie McPherson, Sarah Chambers, Mahua Ghosh, Donna F. Vine
    BMC Women's Health.2023;[Epub]     CrossRef
  • Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial
    Francesco Di Pierro, Ruqqia Sultana, Amna Zia Eusaph, Saida Abrar, Mahroo Bugti, Fauzia Afridi, Umer Farooq, Somia Iqtadar, Fareeha Ghauri, Syeda Makhduma, Shazia Nourin, Ayesha Kanwal, Aasiya Bano, Ali Akbar Bugti, Shah Mureed, Ayesha Ghazal, Romana Irsh
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Investigation of taste function and eating behavior in women with polycystic ovary syndrome
    Sila Cetik, Aylin Acikgoz, Bulent Okan Yildiz
    Appetite.2022; 168: 105776.     CrossRef
  • microRNAs and long non‐coding RNAs as biomarkers for polycystic ovary syndrome
    Mona Tamaddon, Mostafa Azimzadeh, Seyed Mohammad Tavangar
    Journal of Cellular and Molecular Medicine.2022; 26(3): 654.     CrossRef
  • Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients
    Min Min, Xiangyan Ruan, Husheng Wang, Jiaojiao Cheng, Suiyu Luo, Zhongting Xu, Meng Li, Alfred Otto Mueck
    Gynecological Endocrinology.2022; 38(8): 676.     CrossRef
  • Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT
    Renyuan Li, Tingting Mai, Siyuan Zheng, Ying Zhang
    Archives of Gynecology and Obstetrics.2022; 306(5): 1711.     CrossRef
  • Oral contraceptives and stroke: Foes or friends
    Varun Reddy, Megan Wurtz, Shahil H. Patel, Micheline McCarthy, Ami P. Raval
    Frontiers in Neuroendocrinology.2022; 67: 101016.     CrossRef
  • Clinical profiling of polycystic ovary syndrome patients in Kashmir population
    Ahila Ashraf, Rajesh Singh, Shahnawaz Mir
    Matrix Science Pharma.2022; 6(1): 23.     CrossRef
  • Systematic exploration of network pharmacology, in silico modeling and pharmacokinetic profiling for vitamin E in polycystic ovarian syndrome
    Rukaiah Fatma Begum, Sumithra Mohan
    Future Science OA.2020;[Epub]     CrossRef
Close layer
Miscellaneous
Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors
Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima
Endocrinol Metab. 2021;36(2):312-321.   Published online April 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1007
  • 6,007 View
  • 275 Download
  • 18 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   ePub   
Immune-related adverse events (irAEs) affecting the endocrine glands are among the most frequent irAEs induced by immune checkpoint inhibitors (ICIs) and include hypopituitarism, primary adrenal insufficiency, thyrotoxicosis, hypothyroidism, hypoparathyroidism, and type 1 diabetes mellitus. Since the incidence and clinical features of endocrine irAEs vary according to the ICI used, it is important to understand the characteristics of these irAEs and to manage each one appropriately. Since some endocrine irAEs, including adrenal crisis and diabetic ketoacidosis, are potentially life-threatening, predicting the risk of endocrine irAEs before their onset is critical. Several autoantibodies have been detected in patients who develop endocrine irAEs, among which anti-thyroid antibodies may be predictive biomarkers of thyroid dysfunction. In this review, we describe the clinical features of each endocrine irAE induced by ICIs and discuss their potential biomarkers, including autoantibodies.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
    Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima
    Endocrine Journal.2024; 71(1): 23.     CrossRef
  • A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
    Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Esteban C. Gabazza, Yutaka Yano
    Diabetology International.2024;[Epub]     CrossRef
  • Endocrinopathies Associated With Immune Checkpoint Inhibitor Use
    Anupam Kotwal, Randol Kennedy, Nupur Kikani, Sonali Thosani, Whitney Goldner, Afreen Shariff
    Endocrine Practice.2024; 30(6): 584.     CrossRef
  • Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
    Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Naoki Nishio, Shoi
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Adrenal Insufficiency and Thyrotoxicosis Following Combined Immune Checkpoint Inhibitor Use: A Case Report and Literature Review
    Kaoruko Fukushima, Saori Kitayama, Manami Sazuka, Remi Kodera, Kazuhito Oba, Kenji Toyoshima, Yuko Chiba, Hiroshi Yamamoto, Atsushi Araki, Yoshiaki Tamura
    Cureus.2024;[Epub]     CrossRef
  • Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
    Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima
    Endocrine Journal.2024; 71(5): 515.     CrossRef
  • Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report
    Marie Okubo, Yuji Hataya, Kanta Fujimoto, Toshio Iwakura, Naoki Matsuoka
    Journal of Diabetes Investigation.2023; 14(1): 147.     CrossRef
  • Case Report: A Rising Cause of New-Onset Endocrinopathies After Immunotherapy
    Charity Tan, Sarah Hendricks, Kristina Hernandez, Martha Benavides, Rupinderjit Samra
    The Journal for Nurse Practitioners.2023; 19(5): 104582.     CrossRef
  • Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline
    Xin Zhou, Shintaro Iwama, Tomoko Kobayashi, Masahiko Ando, Hiroshi Arima
    The Journal of Clinical Endocrinology & Metabolism.2023; 108(10): e1056.     CrossRef
  • Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
    Liman Huo, Chao Wang, Haixia Ding, Xuelian Shi, Bin Shan, Ruoying Zhou, Ping Liang, Juan Hou
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy
    Aleksandra Basek, Grzegorz K. Jakubiak, Grzegorz Cieślar, Agata Stanek
    Cancers.2023; 15(24): 5786.     CrossRef
  • Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline
    Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tets
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(4): e1620.     CrossRef
  • Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
    Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, Jun Zhao
    Human Vaccines & Immunotherapeutics.2022;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle
    Agnese Barnabei, Andrea Corsello, Rosa Maria Paragliola, Giovanni Maria Iannantuono, Luca Falzone, Salvatore Maria Corsello, Francesco Torino
    Cancers.2022; 14(4): 1057.     CrossRef
  • Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade
    Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Xin Zhou, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Masahiro Morise, Taka
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4115.     CrossRef
  • Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
    Fabiana Pani, Yoshinori Yasuda, Sylvie T Rousseau, Kevin C Bermea, Solmaz Roshanmehr, Rulin Wang, Srinivasan Yegnasubramanian, Patrizio Caturegli, Luigi Adamo
    Journal for ImmunoTherapy of Cancer.2022; 10(12): e005538.     CrossRef
  • Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
    Anupam Kotwal, Mabel Ryder
    Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(5): 517.     CrossRef
Close layer
Special Article
Adrenal gland
Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan Kwon Jung, Young Seok Cho, Jin Chul Paeng, Jae Hyeon Kim, Ohk-Hyun Ryu, Yumie Rhee, Chong Hwa Kim, Eun Jig Lee
Endocrinol Metab. 2021;36(2):322-338.   Published online April 6, 2021
DOI: https://doi.org/10.3803/EnM.2020.908
  • 8,258 View
  • 620 Download
  • 9 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   ePub   
Pheochromocytoma and paraganglioma (PPGLs) are rare catecholamine-secreting neuroendocrine tumors but can be life-threatening. Although most PPGLs are benign, approximately 10% have metastatic potential. Approximately 40% cases are reported as harboring germline mutations. Therefore, timely and accurate diagnosis of PPGLs is crucial. For more than 130 years, clinical, molecular, biochemical, radiological, and pathological investigations have been rapidly advanced in the field of PPGLs. However, performing diagnostic studies to localize lesions and detect metastatic potential can be still challenging and complicated. Furthermore, great progress on genetics has shifted the paradigm of genetic testing of PPGLs. The Korean PPGL task force team consisting of the Korean Endocrine Society, the Korean Surgical Society, the Korean Society of Nuclear Medicine, the Korean Society of Pathologists, and the Korean Society of Laboratory Medicine has developed this position statement focusing on the comprehensive and updated diagnosis for PPGLs.

Citations

Citations to this article as recorded by  
  • A Prospective Comparative Study of 18F-FDOPA PET/CT Versus 123I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
    Changhwan Sung, Hyo Sang Lee, Dong Yun Lee, Yong-il Kim, Jae Eun Kim, Sang Ju Lee, Seung Jun Oh, Tae-Yon Sung, Yu-Mi Lee, Young Hoon Kim, Beom-Jun Kim, Jung-Min Koh, Seung Hun Lee, Jin-Sook Ryu
    Clinical Nuclear Medicine.2024; 49(1): 27.     CrossRef
  • Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study
    Seung Shin Park, Chang Ho Ahn, Seunghoo Lee, Woochang Lee, Won Woong Kim, Yu‐Mi Lee, Su Jin Kim, Tae‐Yon Sung, Kyu Eun Lee, Jung Hee Kim, Seung Hun Lee, Jung‐Min Koh
    Journal of Internal Medicine.2024; 296(1): 68.     CrossRef
  • Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association
    A Ram Hong, Ho-Cheol Kang
    Endocrinology and Metabolism.2023; 38(2): 175.     CrossRef
  • Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma– SIZEPASS
    Helena Hanschell, Salvador Diaz-Cano, Alfredo Blanes, Nadia Talat, Gabriele Galatá, Simon Aylwin, Klaus Martin Schulte
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Interleukin-6-producing paraganglioma as a rare cause of systemic inflammatory response syndrome: a case report
    Yin Young Lee, Seung Min Chung
    Journal of Yeungnam Medical Science.2023; 40(4): 435.     CrossRef
  • (Extremely rare intrapericardial location of paraganglioma)
    Jaroslav Zajíc, Aleš Mokráček, Ladislav Pešl, Jiří Haniš, Dita Schaffelhoferová
    Cor et Vasa.2023; 65(4): 692.     CrossRef
  • A Case of Von Hippel-Lindau Disease With Recurrence of Paraganglioma and No Other Associated Symptoms: The Importance of Genetic Testing and Establishing Follow-Up Policies
    Naoki Okada, Akihiro Shioya, Sumihito Togi, Hiroki Ura, Yo Niida
    Cureus.2023;[Epub]     CrossRef
  • KSNM60 in Nuclear Endocrinology: from the Beginning to the Future
    Chae Moon Hong, Young Jin Jeong, Hae Won Kim, Byeong-Cheol Ahn
    Nuclear Medicine and Molecular Imaging.2022; 56(1): 17.     CrossRef
  • Change of Computed Tomography-Based Body Composition after Adrenalectomy in Patients with Pheochromocytoma
    Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
    Cancers.2022; 14(8): 1967.     CrossRef
  • Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association
    A Ram Hong, Hwa Young Ahn, Bu Kyung Kim, Seong Hee Ahn, So Young Park, Min-Hee Kim, Jeongmin Lee, Sun Wook Cho, Ho-Cheol Kang
    International Journal of Thyroidology.2022; 15(1): 1.     CrossRef
  • Pheochromocytoma with Retroperitoneal Metastasis: A Case Report
    建新 崔
    Advances in Clinical Medicine.2021; 11(05): 2239.     CrossRef
Close layer
Editorial
Close layer
Original Articles
Clinical Study
Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma
Hyein Jung, Kyungwon Kim, Daham Kim, Ju Hyung Moon, Eui Hyun Kim, Se Hoon Kim, Cheol Ryong Ku, Eun Jig Lee
Endocrinol Metab. 2021;36(2):342-350.   Published online March 23, 2021
DOI: https://doi.org/10.3803/EnM.2020.875
  • 4,628 View
  • 148 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
The guanine nucleotide-binding protein, alpha stimulating (GNAS) gene has been associated with growth hormone (GH)-secreting pituitary adenoma. We investigated the prevalence of GNAS mutations in Korean patients with acromegaly and assessed whether mutation status correlated with biochemical or clinical characteristics.
Methods
We studied 126 patients with acromegaly who underwent surgery between 2005 and 2014 at Severance Hospital. We performed GNAS gene analysis and evaluated age, sex, hormone levels, postoperative biochemical remission, and immunohistochemical staining results of the tumor.
Results
GNAS mutations were present in 75 patients (59.5%). Patients with and without GNAS mutations showed similar age distribution and Knosp classification. The proportion of female patients was 76.5% and 48.0% in the GNAS-negative and GNAS-mutation groups, respectively (P=0.006). In immunohistochemical staining, the GNAS-mutation group showed higher GH expression in pituitary tumor tissues than the mutation-negative group (98.7% vs. 92.2%, P=0.015). Patients with GNAS mutations had higher preoperative insulin-like growth factor-1 levels (791.3 ng/mL vs. 697.0 ng/mL, P=0.045) and lower immediate postoperative basal (0.9 ng/mL vs. 1.0 ng/mL, P=0.191) and nadir GH levels (0.3 ng/mL vs. 0.6 ng/mL, P=0.012) in oral glucose tolerance tests. Finally, the GNAS-mutation group showed significantly higher surgical remission rates than the mutation-negative group, both at 1 week and 6 months after surgical resection (70.7% vs. 54.9%, P=0.011; 85.3% vs. 82.4%, P=0.007, respectively).
Conclusion
GNAS mutations in GH-secreting pituitary tumors are associated with higher preoperative insulin-like growth factor-1 levels and surgical remission rates and lower immediate postoperative nadir GH levels. Thus, GNAS mutation status can predict surgical responsiveness in patients with acromegaly.

Citations

Citations to this article as recorded by  
  • Genetic diagnosis in acromegaly and gigantism: From research to clinical practice
    Claudia Ramírez-Rentería, Laura C. Hernández-Ramírez
    Best Practice & Research Clinical Endocrinology & Metabolism.2024; 38(3): 101892.     CrossRef
  • CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
    Haruto Nishida, Yoshihiko Kondo, Takahiro Kusaba, Kazuhiro Kawamura, Yuzo Oyama, Tsutomu Daa, Avaniyapuram Kannan Murugan
    PLOS ONE.2023; 18(2): e0281647.     CrossRef
  • Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
    Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing Liu
    Thoracic Cancer.2023; 14(20): 1980.     CrossRef
  • Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine
    Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee
    Endocrinology and Metabolism.2023; 38(5): 463.     CrossRef
  • Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors
    Mariana Torres-Morán, Alexa L. Franco-Álvarez, Rosa G. Rebollar-Vega, Laura C. Hernández-Ramírez
    Cancers.2023; 15(23): 5685.     CrossRef
Close layer
Clinical Study
Radioactive Parathyroid Adenomas on Sestamibi Scans: Low Parathyroid Hormone Secretory Potential and Large Volume
Sung Hye Kong, Jung Hee Kim, Sang Wan Kim, Chan Soo Shin
Endocrinol Metab. 2021;36(2):351-358.   Published online April 6, 2021
DOI: https://doi.org/10.3803/EnM.2020.823
  • 3,595 View
  • 126 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
We investigated the clinical characteristics of parathyroid adenomas according to radioactivity on 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) single-photon emission computed tomography/computed tomography (SPECT/CT) in primary hyperparathyroidism (PHPT) patients.
Methods
The study included 217 patients diagnosed with PHPT from 2000 to 2019 at Seoul National University Hospital who underwent 99mTc-MIBI SPECT/CT scans. On SPECT/CT, the radioactivity of parathyroid adenomas was measured as the ratio of the mean radioactivity count of the parathyroid adenoma to that of the contralateral thyroid.
Results
Tumors were localized by MIBI scans in 190 patients (MIBI [+] group) and by ultrasound or parathyroid four-dimensional CT in 27 patients (MIBI [–] group). The mean age was 55 years, and mean body mass index was 23.4 kg/m2. Patients in the MIBI (+) group had higher parathyroid hormone (iPTH) and lower 25-hydroxy vitamin D levels than those in the MIBI (–) group (168.0 pg/mL [interquartile range, IQR, 111.0 to 250.7] vs. 134.7 pg/mL [IQR, 98.2 to 191.2], P=0.049; 15.4 ng/mL [IQR, 11.1 to 20.8] vs. 21.2 ng/mL [IQR, 13.9 to 24.8], P=0.012, respectively). Patients in the MIBI (+) group had larger tumor volumes, but lower iPTH/volume ratios than those in the MIBI (–) group (1,216.66 [IQR, 513.40 to 2,663.02], 499.82 mm3 [IQR, 167.77 to 1,229.80], P=0.002; 0.18 [IQR, 0.08 to 0.46], 0.40 pg/mL/mm3 [IQR, 0.16 to 1.29], P=0.016, respectively). Adenoma radioactivity was positively correlated with calcium, iPTH, and volume (r=0.180, P=0.020; r=0.208, P=0.006; r=0.288, P<0.001, respectively), but not with iPTH/volume.
Conclusion
Parathyroid adenomas with positive MIBI scans had larger volumes and higher iPTH than adenomas with negative scans, but lower iPTH per unit volume.

Citations

Citations to this article as recorded by  
  • Protein Signatures of Parathyroid Adenoma according to Tumor Volume and Functionality
    Sung Hye Kong, Jeong Mo Bae, Jung Hee Kim, Sang Wan Kim, Dohyun Han, Chan Soo Shin
    Endocrinology and Metabolism.2024; 39(2): 375.     CrossRef
  • Incidentally detected follicular thyroid carcinoma mimicking parathyroid adenoma on Tc-99m MIBI scan: A case report
    Yeon-Hee Han, Hwan-Jeong Jeong, Sun Young Lee, Seok Tae Lim
    Medicine.2024; 103(18): e38107.     CrossRef
  • Atypical parathyroid tumor: clinical and parathyroid hormone response to surgical treatment
    Antonio Giulio Napolitano, Massimo Monacelli, Valeria Liparulo, Eleonora Coviello, Domenico Pourmolkara, Stefano Avenia, Andrea Polistena
    Annals of Surgical Treatment and Research.2023; 105(2): 76.     CrossRef
  • The Relationship between Planar and SPECT/CT Parameters and Functional Markers in Primary Hyperparathyroidism
    Guler Silov, Serpil Erdogan Ozbodur
    Diagnostics.2023; 13(20): 3182.     CrossRef
Close layer
Clinical Study
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinol Metab. 2021;36(2):359-364.   Published online March 23, 2021
DOI: https://doi.org/10.3803/EnM.2020.890
Correction in: Endocrinol Metab 2022;37(1):181
  • 6,145 View
  • 208 Download
  • 17 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.
Methods
Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.
Conclusion
KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.

Citations

Citations to this article as recorded by  
  • Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines
    Min Joo Kim, Jae Hoon Moon, Eun Kyung Lee, Young Shin Song, Kyong Yeun Jung, Ji Ye Lee, Ji-hoon Kim, Kyungsik Kim, Sue K. Park, Young Joo Park
    Endocrinology and Metabolism.2024; 39(1): 47.     CrossRef
  • It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Kyeong Jin Kim
    Endocrinology and Metabolism.2024; 39(1): 95.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Thyroid‐Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low‐Risk Papillary Thyroid Microcarcinoma in Adults
    Yasuhiro Ito, Akira Miyauchi, Makoto Fujishima, Takuya Noda, Tsutomu Sano, Takahiro Sasaki, Taketoshi Kishi, Tomohiko Nakamura
    World Journal of Surgery.2023; 47(2): 392.     CrossRef
  • Thyroid FNA cytology: The Eastern versus Western perspectives
    Mitsuyoshi Hirokawa, Manon Auger, Chan Kwon Jung, Fabiano Mesquita Callegari
    Cancer Cytopathology.2023; 131(7): 415.     CrossRef
  • To Screen or Not to Screen?
    Do Joon Park
    Endocrinology and Metabolism.2023; 38(1): 69.     CrossRef
  • Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
    Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
    Endocrinology and Metabolism.2023; 38(1): 93.     CrossRef
  • Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience
    Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Akihiro Miya, Naoyoshi Onoda, Minoru Kihara, Takuya Higashiyama, Hiroo Masuoka, Shiori Kawano, Takahiro Sasaki, Mitsushige Nishikawa, Shuji Fukata, Takashi Akamizu, Mitsuru Ito, Eijun Nishihara, Mako Hisakad
    Thyroid®.2023; 33(7): 817.     CrossRef
  • Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status
    Masashi Yamamoto, Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Takahiro Sasaki, Takumi Kudo
    Thyroid®.2023; 33(10): 1182.     CrossRef
  • Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population
    Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Jaseong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chulmin Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Optimal Cutoff Values of the Contact Angle of Tumor on Sonography System for Predicting Extrathyroidal Extension of Papillary Thyroid Carcinoma by Tumor Location
    Ik Beom Shin, Do Hoon Koo, Dong Sik Bae
    Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
  • Thermal Ablation for Papillary Thyroid Microcarcinoma Located in The Isthmus: a Study With 3 Years Of Follow-Up
    Lin Zheng, Fang-yi Liu, Jie Yu, Zhi-gang Cheng, Xiao-ling Yu, Xiao-cong Dong, Zhi-yu Han, Ping Liang
    Future Oncology.2022; 18(4): 471.     CrossRef
  • Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000–2018)
    Elisa Pasqual, Julie Ann Sosa, Yingxi Chen, Sara J. Schonfeld, Amy Berrington de González, Cari M. Kitahara
    Thyroid.2022; 32(4): 397.     CrossRef
  • Management of Low-Risk Thyroid Cancers: Is Active Surveillance a Valid Option? A Systematic Review of the Literature
    Renato Patrone, Nunzio Velotti, Stefania Masone, Alessandra Conzo, Luigi Flagiello, Chiara Cacciatore, Marco Filardo, Vincenza Granata, Francesco Izzo, Domenico Testa, Stefano Avenia, Alessandro Sanguinetti, Andrea Polistena, Giovanni Conzo
    Journal of Clinical Medicine.2021; 10(16): 3569.     CrossRef
  • Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
    Han-sang Baek, Chai-ho Jeong, Jeonghoon Ha, Ja-Seong Bae, Jeong-soo Kim, Dong-Jun Lim, Chul-Min Kim
    Cancer Management and Research.2021; Volume 13: 6721.     CrossRef
  • Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(4): 717.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism